CB
LONGINSIDER SELLCONGRESS BUYCHUBB LTD SWITZ
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
NeutralChubb delivered strong H1 2026 financial performance with 14.6% YoY earnings growth in Q2, beat expectations, and raised guidance to $27–$28.50 EPS for full year 2026 with double-digit growth targets intact. However, significant headwinds are emerging: property market pricing has collapsed 25–40% in key markets, soft conditions are spreading to casualty lines, and the company is intentionally shrinking its large-account and E&S property business due to adverse pricing environment.
Red flags
- •Property market pricing declined 25–40% in North America, London, and larger premiums, described by management as 'dumb' pricing
- •Soft market conditions spreading beyond property to casualty lines with pricing failing to keep pace with loss costs
- •Corporate runoff portfolio experienced $158 million adverse development from molestation-related claims
- •Intentional shrinkage of large-account and E&S property business due to market conditions, signaling strategic retreat from certain segments
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 1.3M | +281K | $422M | 1.2% | +28% | Existing |
| Point72 | Steve Cohen | 32K | +32K | $11M | <0.1% | — | NEW |
| Soros Fund Management | Soros Family Office | 23K | +23K | $7M | 0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where CB ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #34 of this fund's book
- 31ATI INC$485M
- 32CELESTICA INC$466M
- 33CAMDEN PPTY TR$461M
- 34CHUBB LTD SWITZ$422M
- 35ADAPTIVE BIOTECHNOLOGIES COR$416M
- 36BIOMARIN PHARMACEUTICAL INC$399M
- 37SEA LTD$392M
Values are quarter-end position sizes. Shown only for funds where CB ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Wayland Joseph F | Executive Vice President and* | SELL | 9K | $364.54 | $3.10M | 2026-07-28 | ↗ |
| Ortega Juan Luis | Executive Vice President* | SELL | 4K | $322.08 | $1.25M | 2026-06-08 | ↗ |
| Keogh John W | President &COO | SELL | 20K | $321.45 | $6.49M | 2026-05-27 | ↗ |
| Keogh John W | President &COO | SELL | 3K | $321.95 | $0.91M | 2026-05-27 | ↗ |
| ATIEH MICHAEL G | — | SELL | 578 | $329.53 | $0.19M | 2026-05-21 | ↗ |
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Earlier trades (2) — dated outside this quarter's window, not counted in the badges
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.